<DOC>
	<DOCNO>NCT02144155</DOCNO>
	<brief_summary>The Objective study investigate long-term efficacy intranasal oxytocin improvement symptom patient schizophrenia residual symptom dispute adequate treatment antipsychotic medication .</brief_summary>
	<brief_title>Open-label Study Efficacy Intranasal Oxytocin Schizophrenia</brief_title>
	<detailed_description>Approximately 20 patient enrolled participate 6 month flexible dose oxytocin .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Adult men woman , 18 year age old . 2 . Meet DSMIV criterion Schizophrenia 3 . Women childbearing potential must test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study . 4 . Must therapeutic dose 1 2 atypical antipsychotic medication ( example limit Clozapine Olanzapine , Risperidone , Ziprasidone , Aripiprazole , Seroquel ) major dose change least 4 week . 5 . A minimum PANSS total score 55 baseline score least 4 ( moderate ) subscale PANSS ( suspiciousness/persecution ) screening . 6 . Have Clinical Global ImpressionsSeverity ( CGIS ) scale score least 4 ( moderately ill ) baseline ; 7 . Must able communicate effectively investigator study coordinator ability provide inform consent . 8 . Must able use nasal spray 9 . Must demonstrate acceptable degree compliance medication procedure opinion investigator . 1 . Are pregnant breastfeeding ( negative pregnancy test screening ) 2 . A urine drug screen perform screen must show evidence recent use drug abuse 3 . Any active medical condition opinion investigator interfere objective study 4 . Are unsuitable way participate study , opinion investigator . 5 . Another current , primary DSMIV diagnosis Schizophrenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oxytocin</keyword>
</DOC>